Industry withdrawal from psychiatric medication development

Revista Brasileira de Psiquiatria

Volumn 36, Issue 3, 2014, Pages 259-261

  Klein, Donald F ^a   Glick, Ira D ^b  

^a NEW YORK UNIVERSITY CHILD STUDY CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Antipsychotic; Psychopathology; Psychopharmacology; Psychotropic drugs

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS;

CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG INDUSTRY; HUMAN; TRENDS;

CENTRAL NERVOUS SYSTEM AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS;

EID: 84906062243     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-4446-2014-3603     Document Type: Article

References (6)

1. Hyman SE. Revolution stalled. Sci Transl Med. 2012;4:155-11.
2. Insel TR. Next generation treatments for mental disorders. Sci Transl Med. 2012;4:155-19.
3. Miller G. Is pharma running out of brainy ideas? Science. 2010; 329:502-4.
4. Abbott A. Novartis to shut brain research facility. Nature. 2011; 480:161-2.
5. Chassan J. Research design in clinical psychology and psychiatry. New York: Appleton-Century-Crofts; 1967.
6. McGrath PJ, Stewart JW, Petkova E, Quitkin FM, Amsterdam JD, Fawcett J, et al. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. J Clin Psychiatry. 2000;61:518-24.